CANbridge Pharmaceuticals Inc. (1228.HK)

0,330 -0,005 (-1,49 %) À partir de 11:55AM HKT. Marché ouvert.

CANbridge Pharmaceuticals Inc.

Suzhou Industrial Park, Building 21
Unit 18, 6th Floor No. 388 Xinping Street
Suzhou
China
86 10 6478 0016
https://www.canbridgepharma.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 100

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. James Qun Xue M.B.A., Ph.D.	Founder, Chairman of the Board, CEO & Member of Strategic Advisory Board	6,29M	S.O.	1970
Mr. Glenn Hassan	Chief Financial Officer	S.O.	S.O.	1979
Dr. Pauline Li M.B.A., M.D.	Senior VP of Clinical Development & Operations	S.O.	S.O.	S.O.
Ms. Qian Ma	Director of Legal & Compliance, Board Secretary and Joint Company Secretary	S.O.	S.O.	S.O.
Ms. Stella Mao	Senior Director of Public Affairs	S.O.	S.O.	S.O.
Ms. Chris Chen	Vice President of Human Resources	S.O.	S.O.	S.O.
Dr. Gerald F. Cox M.D., Ph.D.	Chief Development Strategist & Interim Chief Medical Officer	S.O.	S.O.	1959
Mr. Marcelo Cheresky	Chief Commercial Officer	S.O.	S.O.	1966
Dr. Wei Zhang	Senior Director & Head of CMC China	S.O.	S.O.	S.O.
Ms. Rebecca Zhang	Senior Vice President of Regulatory Affairs	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en HKD.

Description

CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Livmarli, an oral, minimally-absorbed, reversible IBAT inhibitor for the treatment of alagille syndrome and progressive familial intrahepatic cholestasis. It also engages in the development of CAN008, a CD95-Fc fusion protein that is in Phase 2/3 clinical trial for the treatment of glioblastoma multiforme; CAN106, an anti-C5 mAb that has completed Phase I clinical trial for paroxysmal nocturnal hemoglobinuria; and CAN103, a recombinant human enzyme replacement therapy (ERT) that is in Phase 2/3 clinical trials for gaucher disease. In addition, the company develops CAN107, a fibroblast growth factor 23 (FGF23) blocking antibody for X-linked hypophosphatemia; CAN104, a recombinant human ERT GLA for fabry disease; CAN105, a bispecific antibody for the treatment of hemophilia A; CAN201, a gene therapy program that utilizes adeno-associated virus (AAV) sL65 capsid; CAN202, a gene therapy program utilizing AAV sL65 capsid for pompe disease; and CAN 203, a gene therapy program that utilizes AAV SMN1 for the treatment of spinal muscular atrophy. It has a license agreement with Mirum for the development, commercialization, and manufacturing, under certain conditions, of Livmarli. CANbridge Pharmaceuticals Inc. was founded in 2012 and is headquartered in Suzhou, China.

Gouvernance d’entreprise

L’ISS Governance QualityScore de CANbridge Pharmaceuticals Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.